JADE201 / Jade Biosciences - LARVOL DELTA

JADE201: potentially best-in-class anti-BAFF-R monoclonal antibody for autoimmune diseases (GlobeNewswire) - "A first-in-human study initially evaluating JADE201 in patients with rheumatoid arthritis is expected to begin in the second quarter of 2026, with interim data anticipated in 2027."

First-in-human • New trial • Rheumatoid Arthritis

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases (GlobeNewswire) - "In non-human primate studies, JADE201 achieved dose-dependent BAFF receptor occupancy, sustained B cell depletion after a single subcutaneous dose, and demonstrated approximately a two-fold increase in half-life compared with ianalumab....Jade expects to initiate a first-in-human study evaluating JADE201 in patients with rheumatoid arthritis in the first half of 2026. The randomized, placebo-controlled, single ascending dose trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics, with biomarker-rich endpoints including BAFF-R occupancy, soluble BAFF levels, and B cell subpopulation profiling."

New molecule • New trial • Preclinical • Immunology • Rheumatoid Arthritis